Best of ASCO - 2014 Annual Meeting



Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2019 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

Development and evaluation of a proxy for baseline ECOG PS in advanced non-small cell lung cancer (aNSCLC), bladder cancer (aBCa), and melanoma (aMM): An electronic health records (EHR) study.


Health Services Research, Clinical Informatics, and Quality of Care

2019 ASCO Annual Meeting

Abstract No:

J Clin Oncol 37, 2019 (suppl; abstr e18194)

Author(s): Natalia Sadetsky, Ching-Yi Chuo, Amy J. Davidoff; Genentech, Inc., South San Francisco, CA; Yale School of Public Health, New Haven, CT

Abstract Disclosures


Background: Performance status measured by ECOG PS (ECOG) predicts therapy choice, and overall survival (OS), but often not reported in routine care. EHR data include rich clinical information which Methods: In this retrospective analysis using Flatiron Health EHR-derived database we selected patients diagnosed from 2011-2018 with aNSCLC, aBCa, and aMM and ECOG reported between diagnosis and 1) therapy start, or 2) within 90 days. We used multivariable logistic regressions in a 75% development sample to model associations between selected sociodemographic, clinical and laboratory measures and poor ECOG (2+ vs 0-1) for each cancer. Predictive accuracy was assessed in 25% validation datasets. Kaplan-Meier analysis tested the associations between observed and predicted poor ECOG with OS. Results: The non-missing ECOG samples were 20,697 aNSCLC, 2627 aBCa, and 2558 aMM (out of 50,876, 6955, and 7917 respectively). The proportion of patients with ECOG 2+ ranged from 28.5% for aNSCLC to 15% for aMM. Higher number of comorbid conditions, older age, lowest BMI, higher number of metastases, abnormal albumin and hemoglobin and public insurance were associated with poor ECOG status. Predictive accuracy for poor baseline ECOG was 71.8% for NSLCL, 73.8% for aBca, and 85.4% for aMM). There was a consistent association between OS and observed and predicted baseline ECOG (Table 1). Conclusions: In a large cohort of cancer patients, routinely collected EHR data were used to predict baseline ECOG PS status. Complete ECOG status results may enhance evaluation of cancer treatment patterns and outcomes in EHR data.

OS validation: Median survival x ECOG status

By observed ECOG12.8 vs 4.913.6 vs 4.915.8 vs 4.7
By predicted ECOG*11.1 vs 3.712.1 vs 4.212.9 vs 3.8

*All median survival results differ by ECOG status (2+ vs 0-1) at p < .001

Other Abstracts in this Sub-Category:


1. Longitudinal toxicity analysis with novel summary metrics of lenalidomide maintenance in follicular lymphoma in ECOG-ACRIN 2408.

Meeting: 2019 ASCO Annual Meeting Abstract No: 6511 First Author: Gita Thanarajasingam
Category: Health Services Research, Clinical Informatics, and Quality of Care - Outcomes


2. Comparative effectiveness of proton therapy versus photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer.

Meeting: 2019 ASCO Annual Meeting Abstract No: 6521 First Author: Brian Christopher Baumann
Category: Health Services Research, Clinical Informatics, and Quality of Care - Outcomes


3. Clinical outcomes and cost-effectiveness of breast cancer screening for childhood cancer survivors treated with chest radiation: A comparative modeling study.

Meeting: 2019 ASCO Annual Meeting Abstract No: 6525 First Author: Jennifer Yeh
Category: Health Services Research, Clinical Informatics, and Quality of Care - Outcomes